Evidence map›Paper›PMID 34836536›Full record

ArticleBMC medicine2021

5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.

Jiao Hu, Belaydi Othmane, Anze Yu, Huihuang Li, Zhiyong Cai, Xu Chen, Wenbiao Ren, Jinbo Chen, Xiongbing Zu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 2 pooled it
28.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Jiao HuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Belaydi OthmaneDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Anze YuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Huihuang LiDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Zhiyong CaiDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xu ChenDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Wenbiao RenDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Jinbo ChenDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China. chenjinbo1989@yahoo.com.
Xiongbing ZuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China. zuxbxy@csu.edu.cn.ORCID 0000-0002-6534-1493
Central South University · CNHouston Methodist · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDepicting the heterogeneity and functional characteristics of the tumor microenvironment (TME) is necessary to achieve precision medicine for bladder cancer (BLCA). Although classical molecular subtypes effectively reflect TME heterogeneity and characteristics, their clinical application is limited by several issues.

methodsIn this study, we integrated the Xiangya cohort and multiple external BLCA cohorts to develop a novel 5-methylcytosine (5mC) regulator-mediated molecular subtype system and a corresponding quantitative indicator, the 5mC score. Unsupervised clustering was performed to identify novel 5mC regulator-mediated molecular subtypes. The principal component analysis was applied to calculate the 5mC score. Then, we correlated the 5mC clusters (5mC score) with classical molecular subtypes, immunophenotypes, clinical outcomes, and therapeutic opportunities in BLCA. Finally, we performed pancancer analyses on the 5mC score.

resultsTwo 5mC clusters, including 5mC cluster 1 and cluster 2, were identified. These novel 5mC clusters (5mC score) could accurately predict classical molecular subtypes, immunophenotypes, prognosis, and therapeutic opportunities of BLCA. 5mC cluster 1 (high 5mC score) indicated a luminal subtype and noninflamed phenotype, characterized by lower anticancer immunity but better prognosis. Moreover, 5mC cluster 1 (high 5mC score) predicted low sensitivity to cancer immunotherapy, neoadjuvant chemotherapy, and radiotherapy, but high sensitivity to antiangiogenic therapy and targeted therapies, such as blocking the β-catenin, FGFR3, and PPAR-γ pathways.

conclusionsThe novel 5mC regulator-based subtype system reflects many aspects of BLCA biology and provides new insights into precision medicine in BLCA. Furthermore, the 5mC score may be a generalizable predictor of immunotherapy response and prognosis in pancancers.

Indexed as

Urinary Bladder NeoplasmsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansPrecision MedicineTumor MicroenvironmentBiomarkers, Tumor5-MethylcytosineBladder cancerImmune phenotypeImmunotherapyMolecular subtypeTumor microenvironment

Identifiers

PMID34836536
PMCPMC8627095
OpenAlexW3217221814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.